SurModics (SRDX) Tops Q4 EPS by 8c, Revenues Beat; FY19 EPS Mid-Point Below Consensus, FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Surmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance
November 9, 2018 7:30 AM ESTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook for fiscal 2019.
Summary of Fourth Quarter Fiscal 2018 Highlights and Fiscal 2019 Guidance
Revenue of $23.0 million, an increase of 15% year-over-year GAAP EPS of ($0.13), non-GAAP EPS of $0.05 Submitted application for first in-human study for arteriovenous (AV) access drug coated balloon (DCB) Fiscal... More